

PR-Set7 Protein, Human, Recombinant

General Information

Synonyms:	SET8;SET07;PR-Set7;SET domain containing (lysine methyltransferase) 8;KMT5A
Protein Construction:	A DNA sequence encoding the human SETD8 (NP_065115.3) (Lys 195-His 352) was expressed and purified, with two additional amino acids (Gly & Pro) at the N-terminus. Predicted N terminal: Gly
Species:	Human
Expression Host:	E. coli
Accession:	Q9NQR1-2
Molecular Weight:	18.2 kDa (predicted); 18 kDa (reducing conditions)

QC Testing

Biological Activity:	Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 98 % as determined by SDS-PAGE
Endotoxin:	Please contact us for more information.
Formulation:	Lyophilized from a solution filtered through a 0.22 µm filter, containing 20 mM Tris, 100 mM NaCl, pH 8.0. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

KMT5A (known as PR-Set7/9, SETD8 and SET8), a member of the SET domain containing methyltransferase family specifically targeting H4K20 for methylation, has been implicated in multiple biological processes. Inhibition of KMT5A attenuated proliferation and induced apoptosis. Elevated KMT5A expression was significantly correlated with extrathyroidal extension, lymph node metastasis and advanced pathological stage of papillary thyroid

cancer. KMT5A may be a novel oncogenic factor, specifically a regulator for lipid metabolism in papillary thyroid carcinoma.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481